D. Andes

J. Rabkin, R. Merion, G. Cloud, 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Core Recommendations for Antifungal Stewardship: A Statement of the Mycoses Study Group Education and Research Consortium.

J. Perfect, Melissa D. Johnson, D. Kontoyiannis, 2020, The Journal of infectious diseases.

Achievement of clinical isavuconazole blood concentrations in transplant recipients with isavuconazonium sulphate capsules administered via enteral feeding tube.

R. Rivosecchi, D. Andes, M. Nguyen, 2020, The Journal of antimicrobial chemotherapy.

How Clean Is the Linen at My Hospital? The Mucorales on Unclean Linen Discovery Study of Large United States Transplant and Cancer Centers

J. Perfect, J. Wingard, K. Hanson, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Validated Preclinical Murine Model for Therapeutic Testing against Multidrug Resistant Pseudomonas aeruginosa

J. Gabbard, W. Severson, D. Andes, 2022, bioRxiv.

Calcineurin Controls Drug Tolerance, Hyphal Growth, and Virulence in Candida dubliniensis

J. Heitman, U. Bigol, S. Filler, 2011, Eukaryotic Cell.

Synergistic Effect of Calcineurin Inhibitors and Fluconazole against Candida albicans Bioﬁlms (cid:1)

J. Heitman, D. Andes, J. Nett, 2008 .

Role of Fks1p and Matrix Glucan in Candida albicans Biofilm Resistance to an Echinocandin, Pyrimidine, and Polyene

D. Andes, J. Nett, K. Marchillo, 2010, Antimicrobial Agents and Chemotherapy.

Role of Fks1p and matrix glucan on C. albicans biofilm resistance

D. Andes, J. Nett, K. Marchillo, 2010 .

A Label-Free Cellular Proteomics Approach to Decipher the Antifungal Action of DiMIQ, a Potent Indolo[2,3-b]Quinoline Agent, against Candida albicans Biofilms

D. Andes, R. Zarnowski, J. Gubernator, 2020, International journal of molecular sciences.

Global Identification of Biofilm-Specific Proteolysis in albicans.

Alexander D. Johnson, C. Craik, M. Lohse, 2016 .

Pleiotropic effects of the vacuolar ABC transporter MLT1 of Candida albicans on cell function and virulence

C. d’Enfert, N. Chauhan, A. Mondal, 2016, Biochemical Journal.

Histoplasmosis after solid organ transplant.

J. Baddley, R. Avery, D. Andes, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Free drug 24-hr AUC/MIC is the PK/PD target that correlates with in vivo efficacy of macrolides, azalides, ketolides and clindamycin

W. Craig, D. Andes, S. Kiem, 2002 .

Pharmacokinetics-pharmacodynamics, computer decision support technologies, and antimicrobial stewardship: the compass and rudder.

R. Owens, D. Andes, C. Bulik, 2018, Diagnostic microbiology and infectious disease.

Pharmacokinetics and Pharmacodynamics of?Tetracyclines

W. Craig, D. Andes, 2007 .

Aminoglycosides are useful for severe respiratory tract infections.

W. Craig, D. Andes, 1997, Seminars in respiratory infections.

Antimicrobial Pharmacokinetics and Pharmacodynamics ANTIMICROBIAL PHARMACOKINETICS Kinetics at Site of Infection

D. Andes, 2003 .

Pharmacokinetic and pharmacodynamic properties of antimicrobials in the therapy of respiratory tract infections

D. Andes, 2001, Current opinion in infectious diseases.

Antifungal pharmacokinetics and pharmacodynamics: understanding the implications for antifungal drug resistance.

D. Andes, 2004, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

Pharmacodynamics of fluoroquinolones in experimental models of endocarditis.

W. Craig, D. Andes, 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

In Vivo Activities of Amoxicillin and Amoxicillin-Clavulanate against Streptococcus pneumoniae: Application to Breakpoint Determinations

W. Craig, D. Andes, William A. Craig, 1998, Antimicrobial Agents and Chemotherapy.

Antifungal Therapeutic Drug Monitoring: Established and Emerging Indications

D. Andes, O. Marchetti, A. Pascual, 2008, Antimicrobial Agents and Chemotherapy.

Pharmacokinetics and pharmacodynamics of antifungals.

D. Andes, 2006, Infectious disease clinics of North America.

Characterization and Quantitation of the Pharmacodynamics of Fluconazole in a Neutropenic Murine Disseminated Candidiasis Infection Model

D. Andes, M. V. van Ogtrop, M. V. Ogtrop, 1999, Antimicrobial Agents and Chemotherapy.

Pharmacokinetic-Pharmacodynamic Evaluation of Gepotidacin against Gram-Positive Organisms Using Data from Murine Infection Models

D. Andes, S. Bhavnani, P. Ambrose, 2016, Antimicrobial Agents and Chemotherapy.

Validated Preclinical Mouse Model for Therapeutic Testing against Multidrug-Resistant Pseudomonas aeruginosa Strains

A. Stromberg, J. Gabbard, W. Severson, 2022, Microbiology spectrum.

Rat Indwelling Urinary Catheter Model of Candida albicans Biofilm Infection

H. Sanchez, D. Andes, J. Nett, 2014, Infection and Immunity.

Subtherapeutic ocular penetration of caspofungin and associated treatment failure in Candida albicans endophthalmitis.

D. Andes, T. Nork, G. Gauthier, 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Endemic fungal infections in solid organ and hematopoietic cell transplant recipients enrolled in the Transplant‐Associated Infection Surveillance Network (TRANSNET)

E. Anaissie, G. Lyon, B. Alexander, 2014, Transplant infectious disease : an official journal of the Transplantation Society.

A common vesicle proteome drives fungal biofilm development

A. Mitchell, H. Sanchez, D. Andes, 2022, Proceedings of the National Academy of Sciences of the United States of America.

The Role of In Vitro Susceptibility Testing in the Management of Candida and Aspergillus.

D. Andes, L. Ostrosky-Zeichner, 2017, The Journal of infectious diseases.

Race and invasive fungal infection in solid organ transplant recipients.

G. Mcgwin, G. Lyon, J. Baddley, 2014, Ethnicity & disease.

Comparison of In Vitro Susceptibility Characteristics of Candida Species from Cases of Invasive Candidiasis in Solid Organ and Stem Cell Transplant Recipients: Transplant-Associated Infections Surveillance Network (TRANSNET), 2001 to 2006

J. Baddley, S. Lockhart, J. Ito, 2011, Journal of Clinical Microbiology.

A marine microbiome antifungal targets urgent-threat drug-resistant fungi

Spencer S. Ericksen, Doug R. Braun, Jian Peng, 2020, Science.

A targeted fungal prophylaxis protocol with static dosed fluconazole significantly reduces invasive fungal infection after liver transplantation

D. Andes, D. Foley, L. Fernandez, 2019, Transplant infectious disease : an official journal of the Transplantation Society.

Outcomes by MIC Values for Patients Treated with Isavuconazole or Voriconazole for Invasive Aspergillosis in the Phase 3 SECURE and VITAL Trials

M. Ghannoum, P. Mukherjee, D. Andes, 2018, Antimicrobial Agents and Chemotherapy.

Antifungal therapy and length of hospitalization in transplant patients with invasive aspergillosis.

G. Lyon, M. Boeckh, J. Baddley, 2013, Medical mycology.

Mutant Isolates of Aspergillus fumigatus

D. Andes, K. Marchillo, A. Lepak, 2013 .

Posaconazole Pharmacodynamic Target Determination against Wild-Type and Cyp51 Mutant Isolates of Aspergillus fumigatus in an In Vivo Model of Invasive Pulmonary Aspergillosis

D. Andes, K. Marchillo, A. Lepak, 2012, Antimicrobial Agents and Chemotherapy.

Pulmonary Aspergillosis Model of Invasive In Vivo fumigatus in an Mutant Isolates of Aspergillus Cyp 51 Determination against Wild-Type and Posaconazole Pharmacodynamic Target

D. Andes, K. Marchillo, A. Lepak, 2012 .

In Vitro Echinocandin Susceptibility of Aspergillus Isolates from Patients Enrolled in the Transplant-Associated Infection Surveillance Network

J. Baddley, S. Lockhart, J. Ito, 2011, Antimicrobial Agents and Chemotherapy.

Candida–streptococcal interactions in biofilm-associated oral diseases

D. Krysan, D. Andes, H. Koo, 2018, PLoS pathogens.

Echinocandins

D. Andes, A. Lepak, 2021, Encyclopedia of Mycology.

Pharmacodynamic Target Evaluation of a Novel Oral Glucan Synthase Inhibitor, SCY-078 (MK-3118), Using an In Vivo Murine Invasive Candidiasis Model

D. Andes, K. Marchillo, A. Lepak, 2014, Antimicrobial Agents and Chemotherapy.

Correlation of MIC with Outcome for Candida Species Tested against Caspofungin, Anidulafungin, and Micafungin: Analysis and Proposal for Interpretive MIC Breakpoints

M. Ghannoum, B. Alexander, Steven D. Brown, 2008, Journal of Clinical Microbiology.

Materials and Methods Comparative Analysis of Candida Biofi Lm Quantitation Assays

D. Andes, J. Nett, H. Taff, 2022 .

Commensal Protection of Staphylococcus aureus against Antimicrobials by Candida albicans Biofilm Matrix

P. van Dijck, D. Andes, M. Jabra-Rizk, 2016, mBio.

Structural and functional analysis of EntV reveals a 12 amino acid fragment protective against fungal infections

M. Lorenz, P. Stogios, E. Evdokimova, 2022, Nature Communications.

Continuous flow synthesis and antimicrobial evaluation of NHC* silver carboxylate derivatives of SBC3 in vitro and in vivo.

M. Baumann, S. Patil, D. Andes, 2020, Metallomics : integrated biometal science.

Thalassosamide, a Siderophore Discovered from the Marine-Derived Bacterium Thalassospira profundimaris.

Doug R. Braun, F. Hoffmann, D. Andes, 2017, Journal of natural products.

Continuous infusion of amphotericin B deoxycholate for the treatment of life-threatening Candida infections.

S. Seyedmousavi, D. Andes, P. Verweij, 2013, American journal of respiratory and critical care medicine.

APX001 Pharmacokinetic/Pharmacodynamic Target Determination against Aspergillus fumigatus in an In Vivo Model of Invasive Pulmonary Aspergillosis

H. Sanchez, D. Andes, K. Marchillo, 2019, Antimicrobial Agents and Chemotherapy.

International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus.

S. Seyedmousavi, D. Denning, A. Chowdhary, 2015, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

Prospective Multicenter International Surveillance of Azole Resistance in Aspergillus fumigatus

P. Hauser, J. Baddley, D. Denning, 2015, Emerging infectious diseases.

Beta -1,3 glucan as a test for central venous catheter biofilm infection.

D. Andes, J. Nett, K. Marchillo, 2007, The Journal of infectious diseases.

Application of 3D NMR for Structure Determination of Peptide Natural Products.

Doug R. Braun, M. Tonelli, D. Andes, 2015, The Journal of organic chemistry.

Isavuconazole Pharmacodynamic Target Determination for Candida Species in an In Vivo Murine Disseminated Candidiasis Model

D. Andes, D. Diekema, K. Marchillo, 2013, Antimicrobial Agents and Chemotherapy.

Isavuconazole Pharmacodynamic Target Determination for Candida species in an In vivo 1

D. Andes, D. Diekema, K. Marchillo, 2013 .

GliZ, a Transcriptional Regulator of Gliotoxin Biosynthesis, Contributes to Aspergillus fumigatus Virulence

J. Frisvad, K. Nielsen, S. Balajee, 2006, Infection and Immunity.

In Vivo Pharmacodynamic Activity of the Glycopeptide Dalbavancin

W. Craig, D. Andes, 2007, Antimicrobial Agents and Chemotherapy.

Pharmacodynamics of the New Fluoroquinolone Gatifloxacin in Murine Thigh and Lung Infection Models

W. Craig, D. Andes, 2002, Antimicrobial Agents and Chemotherapy.

Insights into fungal pathogenesis from the iatrogenic epidemic of Exserohilum rostratum fungal meningitis.

A. Casadevall, D. Andes, 2013, Fungal genetics and biology : FG & B.

Candida albicans FRE8 encodes a member of the NADPH oxidase family that produces a burst of ROS during fungal morphogenesis

V. Culotta, B. Cormack, H. Sanchez, 2017, PLoS pathogens.

Exploiting the vulnerable active site of a copper-only superoxide dismutase to disrupt fungal pathogenesis

V. Culotta, H. Sanchez, D. Andes, 2018, The Journal of Biological Chemistry.

Primary cutaneous cryptococcosis in immunocompetent and immunocompromised hosts.

J. Christianson, D. Andes, W. Engber, 2003, Medical mycology.

Optimizing Echinocandin Dosing and Susceptibility Breakpoint Determination via In Vivo Pharmacodynamic Evaluation against Candida glabrata with and without fks Mutations

M. Castanheira, M. Pfaller, D. Andes, 2012, Antimicrobial Agents and Chemotherapy.

Specialized Metabolites Reveal Evolutionary History and Geographic Dispersion of a Multilateral Symbiosis

J. Clardy, D. Andes, C. Currie, 2021, ACS central science.

Folate Functionalized Lipid Nanoparticles for Targeted Therapy of Methicillin-Resistant Staphylococcus aureus

H. Abdelhady, Duy Luong, A. Iyer, 2021, Pharmaceutics.

Pharmacokinetics and pharmacodynamics of antibiotics in meningitis.

W. Craig, D. Andes, 1999, Infectious disease clinics of North America.

Contributions of Extracellular Vesicles to Fungal Biofilm Pathogenesis.

D. Andes, Marienela Y Heredia, 2021, Current topics in microbiology and immunology.

Putative Role of (cid:2) -1,3 Glucans in Candida albicans Bioﬁlm Resistance (cid:1)

D. Andes, J. Nett, K. Marchillo, 2007 .

Small-Molecule Morphogenesis Modulators Enhance the Ability of 14-Helical β-Peptides To Prevent Candida albicans Biofilm Formation

Sean P. Palecek, Nathan B Wang, D. M. Lynn, 2019, Antimicrobial Agents and Chemotherapy.

Autochthonous furuncular myiasis in the United States: case report and literature review.

D. Andes, N. Safdar, D. K. Young, 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Extracellular Vesicles Contribute to Mixed-Fungal Species Competition during Biofilm Initiation

A. Mitchell, D. Andes, R. Zarnowski, 2022, mBio.

Development of New Strategies for Echinocandins: Progress in Translational Research.

T. Walsh, D. Andes, N. Azie, 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Identification of antifungal natural products via Saccharomyces cerevisiae bioassay: insights into macrotetrolide drug spectrum, potency and mode of action.

B. Shen, Zhiguo Yu, D. Andes, 2013, Medical mycology.

Non-toxic antimicrobials that evade drug resistance

S. Lindquist, M. Burke, L. Whitesell, 2015, Nature chemical biology.

Antifungal Agents Pharmacokinetics and Pharmacodynamics of Amphotericin B

D. Andes, 2007 .

Clinical utility of antifungal pharmacokinetics and pharmacodynamics

D. Andes, 2004, Current opinion in infectious diseases.

Global guideline for the diagnosis and management of the endemic mycoses: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology.

N. Ampel, J. Chan, T. Hohl, 2021, The Lancet. Infectious diseases.

In Vivo Pharmacokinetics and Pharmacodynamics of APX001 against Candida spp. in a Neutropenic Disseminated Candidiasis Mouse Model

D. Andes, K. Marchillo, P. Ambrose, 2018, Antimicrobial Agents and Chemotherapy.

Pharmacodynamics of a Long-Acting Echinocandin, CD101, in a Neutropenic Invasive-Candidiasis Murine Model Using an Extended-Interval Dosing Design

D. Andes, P. Ambrose, A. Lepak, 2017, Antimicrobial Agents and Chemotherapy.

Report of successful prolonged antifungal therapy for refractory allergic fungal sinusitis.

R. Bush, R. Proctor, D. Andes, 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Pyridine-2,6-Dithiocarboxylic Acid and Its Metal Complexes: New Inhibitors of New Delhi Metallo β-Lactamase-1

Chris S. Thomas, Doug R. Braun, G. Phillips, 2020, Marine drugs.

Development and Validation of an In Vivo Candida albicans Bioﬁlm Denture Model (cid:1)

D. Andes, J. Nett, K. Marchillo, 2010 .

Reduced Biocide Susceptibility in Candida albicans Bioﬁlms (cid:1)

D. Andes, K. Guite, J. Nett, 2008 .

CNS pharmacokinetics of antifungal agents

D. Andes, S. Kethireddy, 2007 .

Mice-Lactamases , in the Thighs of Neutropenic β Including Strains with Extended-Spectrum aeruginosa and Enterobacteriaceae , Tazobactam against Pseudomonas Cephalosporin , with and without Activities of Ceftolozane , a New In Vivo

D. Andes, 2013 .

In Vivo Activities of Ceftolozane, a New Cephalosporin, with and without Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, Including Strains with Extended-Spectrum β-Lactamases, in the Thighs of Neutropenic Mice

W. Craig, D. Andes, 2012, Antimicrobial Agents and Chemotherapy.

Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations.

D. Andes, Jeannina A Smith, 2008, Therapeutic drug monitoring.

Determination of Pharmacodynamic Target Exposures for Rezafungin against Candida tropicalis and Candida dubliniensis in the Neutropenic Mouse Disseminated Candidiasis Model

D. Andes, A. Lepak, Miao Zhao, 2019, Antimicrobial Agents and Chemotherapy.

Optimizing a Candida Bioﬁlm Microtiter Plate Model for Measurement of Antifungal Susceptibility by Tetrazolium Salt Assay (cid:1)

D. Andes, J. Nett, Mike T. Cain, 2011 .

In Vivo Pharmacodynamic Activity of Daptomycin

W. Craig, D. Andes, N. Safdar, 2004, Antimicrobial Agents and Chemotherapy.

Engineering of Streptomyces platensis MA7339 for overproduction of platencin and congeners.

M. Smanski, B. Shen, Zhiguo Yu, 2010, Organic letters.

In Vivo Pharmacokinetics and Pharmacodynamics of a New Triazole, Voriconazole, in a Murine Candidiasis Model

D. Andes, K. Marchillo, R. Conklin, 2003, Antimicrobial Agents and Chemotherapy.

Pharmacokinetic-Pharmacodynamic Comparison of Amphotericin B (AMB) and Two Lipid-Associated AMB Preparations, Liposomal AMB and AMB Lipid Complex, in Murine Candidiasis Models

D. Andes, N. Safdar, K. Marchillo, 2006, Antimicrobial Agents and Chemotherapy.

Pharmacodynamics of Amphotericin B in a Neutropenic-Mouse Disseminated-Candidiasis Model

D. Andes, R. Conklin, T. Stamsted, 2001, Antimicrobial Agents and Chemotherapy.

Use of Pharmacokinetic-Pharmacodynamic Analyses To Optimize Therapy with the Systemic Antifungal Micafungin for Invasive Candidiasis or Candidemia

D. Andes, Varsha Iyer, S. Bhavnani, 2011, Antimicrobial Agents and Chemotherapy.

Variability and exposure–response relationships of isavuconazole plasma concentrations in the Phase 3 SECURE trial of patients with invasive mould diseases

D. Andes, A. Groll, M. Engelhardt, 2018, The Journal of antimicrobial chemotherapy.

Antifungal pharmacokinetics and pharmacodynamics.

D. Andes, A. Lepak, 2015, Cold Spring Harbor perspectives in medicine.

We can do better: a fresh look at echinocandin dosing.

D. Andes, S. Bhavnani, P. Ambrose, 2018, Journal of Antimicrobial Chemotherapy.

We can do better: a fresh look at echinocandin dosing.

D. Andes, S. Bhavnani, P. Ambrose, 2018, The Journal of antimicrobial chemotherapy.

In Vivo Comparison of the Pharmacodynamic Targets for Echinocandin Drugs against Candida Species

M. Pfaller, D. Andes, D. Diekema, 2010, Antimicrobial Agents and Chemotherapy.

Impact of Antimicrobial Dosing Regimen on Evolution of Drug Resistance In Vivo: Fluconazole and Candida albicans

D. Andes, J. Nett, K. Marchillo, 2006, Antimicrobial Agents and Chemotherapy.

Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America.

J. Sobel, T. Calandra, D. Benjamin, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Isavuconazole Concentration in Real-World Practice: Consistency with Results from Clinical Trials

T. Walsh, D. Andes, L. Kovanda, 2018, Antimicrobial Agents and Chemotherapy.

Voriconazole Therapeutic Drug Monitoring

D. Andes, N. Safdar, S. Bhavnani, 2006, Antimicrobial Agents and Chemotherapy.

In Vivo Pharmacodynamics of Antifungal Drugs in Treatment of Candidiasis

D. Andes, 2003, Antimicrobial Agents and Chemotherapy.

Impact of MIC Range for Pseudomonas aeruginosa and Streptococcus pneumoniae on the Ceftolozane In Vivo Pharmacokinetic/Pharmacodynamic Target

W. Craig, D. Andes, K. Marchillo, 2014, Antimicrobial Agents and Chemotherapy.

Development and Characterization of an In Vivo Central Venous Catheter Candida albicans Biofilm Model

D. Andes, J. Nett, K. Marchillo, 2004, Infection and Immunity.

Model‐Informed Drug Development for Anti‐Infectives: State of the Art and Future

E. Mills, C. Rayner, Virna J. A. Schuck, 2021, Clinical pharmacology and therapeutics.

The Role of New Posaconazole Formulations in the Treatment of Candida albicans Infections: Data from an In Vitro Pharmacokinetic-Pharmacodynamic Model

M. Arendrup, D. Andes, J. Meletiadis, 2021, Antimicrobial Agents and Chemotherapy.

Toward Harmonization of Voriconazole CLSI and EUCAST Breakpoints for Candida albicans Using a Validated In Vitro Pharmacokinetic/Pharmacodynamic Model

M. Arendrup, D. Andes, J. Meletiadis, 2020, Antimicrobial Agents and Chemotherapy.

Animal Models to Evaluate Anti-infective Pharmacodynamics

D. Andes, A. Lepak, 2016 .

Antifungal PK/PD Considerations in Fungal Pulmonary Infections

D. Andes, A. Lepak, Alexander Lepak1 , 2, 2011, Seminars in respiratory and critical care medicine.

Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria.

M. Ghannoum, B. Alexander, Steven D. Brown, 2011, Diagnostic microbiology and infectious disease.

Fungal sepsis: optimizing antifungal therapy in the critical care setting.

D. Andes, A. Lepak, 2011, Critical care clinics.

Association of Fluconazole Pharmacodynamics with Mortality in Patients with Candidemia

J. Baddley, D. Andes, S. Moser, 2008, Antimicrobial Agents and Chemotherapy.

Pharmacodynamics of antifungal drugs: A strategy to optimize efficacy

D. Andes, A. Lepak, 2008 .

In Vivo Pharmacodynamics of a New Triazole, Ravuconazole, in a Murine Candidiasis Model

D. Andes, K. Marchillo, R. Conklin, 2003, Antimicrobial Agents and Chemotherapy.

In vivo characterization of the pharmacodynamics of the new triazole, posaconazole , in a murine candidiasis model

D. Andes, K. Marchillo, R. Conklin, 2002 .

Pharmacokinetics and pharmacodynamics of antibiotics in otitis media.

W. Craig, D. Andes, 1996, The Pediatric infectious disease journal.

Novel Entries in a Fungal Biofilm Matrix Encyclopedia

J. Bernhardt, W. M. Westler, A. Mitchell, 2014, mBio.

Comparative Phenotypic Analysis of the Major Fungal Pathogens Candida parapsilosis and Candida albicans

Desmond G. Higgins, Markus S. Schröder, Ken Haynes, 2014, PLoS pathogens.

Preventing Pseudomonas aeruginosa Biofilms on Indwelling Catheters by Surface-Bound Enzymes.

B. Hatton, D. Asker, P. Howell, 2021, ACS applied bio materials.

Searching for new derivatives of neocryptolepine: synthesis, antiproliferative, antimicrobial and antifungal activities.

D. Andes, A. Kozubek, W. Peczyńska-Czoch, 2014, European journal of medicinal chemistry.

The synthesis of indolo[2,3-b]quinoline derivatives with a guanidine group: highly selective cytotoxic agents.

D. Andes, J. Wietrzyk, M. Świtalska, 2015, European journal of medicinal chemistry.

Pharmacodynamics of a New Triazole, Posaconazole, in a Murine Model of Disseminated Candidiasis

D. Loebenberg, D. Andes, K. Marchillo, 2004, Antimicrobial Agents and Chemotherapy.

Pharmacodynamics of a New Streptogramin, XRP 2868, in Murine Thigh and Lung Infection Models

W. Craig, D. Andes, 2006, Antimicrobial Agents and Chemotherapy.

Chemical Exchanges between Multilateral Symbionts.

C. Rock, J. Clardy, D. Andes, 2021, Organic letters.

Rationale for Reading Fluconazole MICs at 24 Hours Rather than 48 Hours When Testing Candida spp. by the CLSI M27-A2 Standard Method

M. Ghannoum, B. Alexander, Steven D. Brown, 2008, Antimicrobial Agents and Chemotherapy.

The transcriptional network controlling biofilm development in Candida albicans

Alexander D. Johnson, B. Tuch, Q. Mitrovich, 2012 .

Pyonitrins A–D: Chimeric Natural Products Produced by Pseudomonas protegens

J. Clardy, D. Andes, C. Currie, 2019, Journal of the American Chemical Society.

Fungal biofilms, drug resistance, and recurrent infection.

A. Mitchell, D. Andes, Jigar V. Desai, 2014, Cold Spring Harbor perspectives in medicine.

Hsp90 Governs Dispersion and Drug Resistance of Fungal Biofilms

L. Cowen, R. Rajendran, D. Andes, 2011, PLoS pathogens.

Interface of Candida albicans Biofilm Matrix-Associated Drug Resistance and Cell Wall Integrity Regulation

H. Sanchez, D. Andes, J. Nett, 2011, Eukaryotic Cell.

Exophiala jeanselmei infection in a heart transplant recipient successfully treated with oral terbinafine.

D. Andes, W. Agger, Joshua W Burgess, 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

A Mycoses Study Group International Prospective Study of Phaeohyphomycosis: An Analysis of 99 Proven/Probable Cases

B. Alexander, J. Baddley, C. Seas, 2017, Open forum infectious diseases.

Phaeohyphomycosis in transplant recipients: Results from the Transplant Associated Infection Surveillance Network (TRANSNET).

G. Lyon, B. Alexander, J. Baddley, 2015, Medical mycology.

Premixed antibiotic bone cement: an in vitro comparison of antimicrobial efficacy.

D. Andes, M. Squire, Jonathan Thompson, 2008, The Journal of arthroplasty.

Function of Candida albicans Adhesin Hwp1 in Biofilm Formation

A. Mitchell, D. Andes, C. Nobile, 2006, Eukaryotic Cell.

Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.

J. Sobel, A. Reboli, T. Walsh, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Clinical Pharmacodynamic Index Identification for Micafungin in Esophageal Candidiasis: Dosing Strategy Optimization

D. Andes, S. Bhavnani, A. Lepak, 2013, Antimicrobial Agents and Chemotherapy.

Blastomycosis in solid organ transplant recipients

D. Andes, N. Safdar, B. Klein, 2007, Transplant infectious disease : an official journal of the Transplantation Society.

Development and Validation of an In Vivo Candida albicans Biofilm Denture Model

D. Andes, J. Nett, K. Marchillo, 2010, Infection and Immunity.

In Vivo Characterization of the Pharmacodynamics of Flucytosine in a Neutropenic Murine Disseminated Candidiasis Model

D. Andes, M. V. van Ogtrop, M. V. Ogtrop, 2000, Antimicrobial Agents and Chemotherapy.

Clinical pharmacodynamics of antifungals.

D. Andes, 2003, Infectious disease clinics of North America.

CNS pharmacokinetics of antifungal agents.

D. Andes, S. Kethireddy, 2007, Expert opinion on drug metabolism & toxicology.

Identifi cation of antifungal natural products via Saccharomyces cerevisiae bioassay : insights into macrotetrolide drug spectrum , potency and mode of action

B. Shen, D. Andes, B. Klein, 2013 .

D. Andes, S. Kethireddy, 2007 .

Combination Antifungal Therapy Involving Amphotericin B, Rapamycin and 5-Fluorocytosine Using PEG-Phospholipid Micelles

G. Kwon, D. Andes, K. Knilans, 2008, Pharmaceutical Research.

Antifungal Efficacy of an Intravenous Formulation Containing Monomeric Amphotericin B, 5-Fluorocytosine, and Saline for Sodium Supplementation

G. Kwon, D. Andes, Jeong Yeon Kang, 2017, Pharmaceutical Research.

Optimizing antifungal choice and administration

D. Andes, 2013, Current medical research and opinion.

Review Optimizing antifungal choice and administration

D. Andes, 2013 .

Monitoring and impact of fluconazole serum and cerebrospinal fluid concentration in HIV‐associated cryptococcal meningitis‐infected patients

S. Filler, D. Andes, W. Manosuthi, 2010, HIV medicine.

Voriconazole Use for Endemic Fungal Infections

L. Baddour, B. Spellberg, D. Andes, 2009, Antimicrobial Agents and Chemotherapy.

Tissue Distribution and Elimination of Isavuconazole following Single and Repeat Oral-Dose Administration of Isavuconazonium Sulfate to Rats

D. Andes, A. Schmitt-Hoffmann, W. Hope, 2017, Antimicrobial Agents and Chemotherapy.

Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods.

M. Pfaller, D. Andes, D. Diekema, 2010, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

Predictors and outcomes of candiduria in renal transplant recipients.

R. Gangnon, J. Pirsch, D. Andes, 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Mechanisms of Candida biofilm drug resistance.

Kaitlin F. Mitchell, D. Andes, K. Mitchell, 2013, Future microbiology.

Large-scale production and isolation of Candida biofilm extracellular matrix

H. Sanchez, D. Andes, R. Zarnowski, 2016, Nature Protocols.

Patterns of Susceptibility of Aspergillus Isolates Recovered from Patients Enrolled in the Transplant-Associated Infection Surveillance Network

J. Baddley, J. Ito, D. Kontoyiannis, 2009, Journal of Clinical Microbiology.

Has the Optimal Therapy for Invasive Candidiasis Now Been Defined?

D. Andes, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

JCM00854-09 REVISION 1 Susceptibility Patterns of Aspergillus Isolates Recovered from Patients Enrolled in the Transplant Associated Infection Surveillance Network (TRANSNET)

J. Baddley, J. Ito, D. Kontoyiannis, 2009 .

In Vivo Pharmacodynamic Target Investigation for Micafungin against Candida albicans and C. glabrata in a Neutropenic Murine Candidiasis Model

M. Pfaller, D. Andes, D. Diekema, 2008, Antimicrobial Agents and Chemotherapy.

In Vivo Pharmacodynamic Characterization of Anidulafungin in a Neutropenic Murine Candidiasis Model

M. Pfaller, D. Andes, D. Diekema, 2007, Antimicrobial Agents and Chemotherapy.

Results Three-step Synthesis of Amb Ureas Nontoxic Antimicrobials That Evade Drug Resistance

S. Lindquist, M. Burke, L. Whitesell, 2022 .

Multilaboratory Testing of Two-Drug Combinations of Antifungals against Candida albicans, Candida glabrata, and Candida parapsilosis

M. Ghannoum, S. Lockhart, T. Walsh, 2011, Antimicrobial Agents and Chemotherapy.

The Role of Second-Generation Antifungal Triazoles for Treatment of the Endemic Mycoses

D. Andes, A. Freifeld, J. Bariola, 2010, Current infectious disease reports.

Drug-Drug Interaction Associated with Mold-Active Triazoles among Hospitalized Patients

Eric Q. Wu, Caroline Kelley, D. Andes, 2016, Antimicrobial Agents and Chemotherapy.

The Extracellular Matrix of Fungal Biofilms.

Kaitlin F. Mitchell, D. Andes, K. Mitchell, 2016, Advances in experimental medicine and biology.

The Role of Biofilm Matrix in Mediating Antifungal Resistance

D. Andes, J. Nett, 2015 .

Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database.

Thomas J Walsh, Randall Walker, Kieren A Marr, 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Protein Binding: Do We Ever Learn?

O. Cars, W. Craig, M. Zeitlinger, 2011, Antimicrobial Agents and Chemotherapy.

MINIREVIEW Protein Binding: Do We Ever Learn?

O. Cars, W. Craig, M. Zeitlinger, 2011 .

HdaA, a class 2 histone deacetylase of Aspergillus fumigatus, affects germination and secondary metabolite production.

D. Andes, N. Keller, Inhyung Lee, 2009, Fungal genetics and biology : FG & B.

Regulatory Level of Evidence and Practicality in Antifungal Use Decisions for Less Common Fungal Diseases.

D. Andes, 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Pharmacokinetics of extended dose intervals of micafungin in haematology patients: optimizing antifungal prophylaxis

D. Andes, K. Theunissen, R. ter Heine, 2018, The Journal of antimicrobial chemotherapy.

Efficacy of Extended-Interval Dosing of Micafungin Evaluated Using a Pharmacokinetic/Pharmacodynamic Study with Humanized Doses in Mice

D. Andes, K. Marchillo, A. Lepak, 2015, Antimicrobial Agents and Chemotherapy.

Putative Role of β-1,3 Glucans in Candida albicans Biofilm Resistance

D. Andes, J. Nett, K. Marchillo, 2006, Antimicrobial Agents and Chemotherapy.

Multicenter Collaborative Study of the Interaction of Antifungal Combinations against Candida Spp. by Loewe Additivity and Bliss Independence-Based Response Surface Analysis

M. Ghannoum, S. Lockhart, M. Pfaller, 2022, Journal of fungi.

Impact of In Vivo Triazole and Echinocandin Combination Therapy for Invasive Pulmonary Aspergillosis: Enhanced Efficacy against Cyp51 Mutant Isolates

D. Andes, K. Marchillo, A. Lepak, 2013, Antimicrobial Agents and Chemotherapy.

Time Course of Microbiologic Outcome and Gene Expression in Candida albicans during and following In Vitro and In Vivo Exposure to Fluconazole

D. Andes, J. Nett, K. Marchillo, 2006, Antimicrobial Agents and Chemotherapy.

Fungal Super Glue: The Biofilm Matrix and Its Composition, Assembly, and Functions

Kaitlin F. Mitchell, D. Andes, K. Mitchell, 2016, PLoS pathogens.

Safety and Outcomes of Open-Label Deferasirox Iron Chelation Therapy for Mucormycosis

B. Spellberg, A. Ibrahim, T. Walsh, 2009, Antimicrobial Agents and Chemotherapy.

Candida albicans biofilm–induced vesicles confer drug resistance through matrix biogenesis

Kaitlin F. Mitchell, J. Bernhardt, A. Mitchell, 2018, PLoS biology.

Use of an animal model of disseminated candidiasis in the evaluation of antifungal therapy.

D. Andes, 2005, Methods in molecular medicine.

Pharmacodynamic Optimization for the Treatment of Invasive Candida auris Infection

E. Berkow, S. Lockhart, D. Andes, 2017, Antimicrobial Agents and Chemotherapy.

Reduced Biocide Susceptibility in Candida albicans Biofilms

D. Andes, K. Guite, J. Nett, 2008, Antimicrobial Agents and Chemotherapy.

Exposure-Response Relationships for Isavuconazole in Patients with Invasive Aspergillosis and Other Filamentous Fungi

P. Bonate, S. Mujais, D. Andes, 2017, Antimicrobial Agents and Chemotherapy.

Community participation in biofilm matrix assembly and function

Kaitlin F. Mitchell, A. Mitchell, H. Sanchez, 2015, Proceedings of the National Academy of Sciences.

Use of Pharmacodynamic Indices To Predict Efficacy of Combination Therapy In Vivo

W. Craig, D. Andes, J. Mouton, 1999, Antimicrobial Agents and Chemotherapy.

Candida Biofilm Tolerance: Comparison of Planktonic and Biofilm Resistance Mechanisms

D. Andes, E. Dominguez, 2017 .

Assessment of the Role of 1,3-β-d-Glucan Testing for the Diagnosis of Invasive Fungal Infections in Adults.

D. Andes, C. Clancy, L. Ostrosky-Zeichner, 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Septic thrombosis of the basilic, axillary, and subclavian veins caused by a peripherally inserted central venous catheter.

D. Maki, D. Andes, C. Acher, 1998, The American journal of medicine.

Animal model pharmacokinetics and pharmacodynamics: a critical review.

W. Craig, D. Andes, W A Craig, 2002, International journal of antimicrobial agents.

Treatment of infections with ESBL-producing organisms: pharmacokinetic and pharmacodynamic considerations.

W. Craig, D. Andes, W A Craig, 2005, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Polymyxin Susceptibility Testing and Interpretive Breakpoints: Recommendations from the United States Committee on Antimicrobial Susceptibility Testing (USCAST)

Ronald N. Jones, G. Drusano, D. Andes, 2019, Antimicrobial Agents and Chemotherapy.

Infections after the use of alemtuzumab in solid organ transplant recipients: a comparative study.

S. Knechtle, D. Andes, N. Safdar, 2010, Diagnostic microbiology and infectious disease.

Synthesis and antibacterial activity of doxycycline neoglycosides.

J. Thorson, D. Andes, K. Marchillo, 2013, Journal of natural products.

In Vivo Fluconazole Pharmacodynamics and Resistance Development in a Previously Susceptible Candida albicans Population Examined by Microbiologic and Transcriptional Profiling

D. Andes, J. Nett, K. Marchillo, 2006, Antimicrobial Agents and Chemotherapy.

Formation and characterization of biofilms formed by salt-tolerant yeast strains in seawater-based growth medium

H. Sanchez, D. Andes, R. Zarnowski, 2021, Applied Microbiology and Biotechnology.

In Vivo Pharmacodynamics of New Lipopeptide MX-2401

W. Craig, D. Andes, T. Stamstad, 2010, Antimicrobial Agents and Chemotherapy.

Pharmacodynamics of Quinolone Antimicrobial Agents

W. Craig, D. Andes, 2003 .

In Vivo Pharmacokinetics and Pharmacodynamics of ZTI-01 (Fosfomycin for Injection) in the Neutropenic Murine Thigh Infection Model against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa

D. Andes, P. Ambrose, A. Lepak, 2017, Antimicrobial Agents and Chemotherapy.

Use of Preclinical Data for Selection of a Phase II/III Dose for Evernimicin and Identification of a Preclinical MIC Breakpoint

G. Drusano, W. Craig, D. Andes, 2001, Antimicrobial Agents and Chemotherapy.

The antimicrobial potential of Streptomyces from insect microbiomes

Chris S. Thomas, G. Ananiev, F. Hoffmann, 2019, Nature Communications.

In vivo infection models in the pre‐clinical pharmacokinetic/pharmacodynamic evaluation of antimicrobial agents

D. Andes, A. Lepak, 2017, Current opinion in pharmacology.

The antimicrobial potential of Streptomyces from insect microbiomes

Miao Zhao, Fan Zhang, Chris S. Thomas, 2019, Nature Communications.

Parenteral versus oral antibiotic therapy.

W. Craig, D. Andes, 1995, The Medical clinics of North America.

Portrait of Candida albicans Adherence Regulators

F. Lanni, A. Mitchell, C. Woolford, 2012, PLoS pathogens.

Conserved and Divergent Roles of Bcr1 and CFEM Proteins in Candida parapsilosis and Candida albicans

G. Butler, A. Guida, D. Andes, 2011, PloS one.

Biofilm Matrix Regulation by Candida albicans Zap1

A. Mitchell, O. Homann, A. Nantel, 2009, PLoS biology.

Distinct roles of the 7‐transmembrane receptor protein Rta3 in regulating the asymmetric distribution of phosphatidylcholine across the plasma membrane and biofilm formation in Candida albicans

D. Andes, C. Nobile, S. Rastogi, 2017, Cellular microbiology.

Distinct roles of the 7-transmembrane receptor protein Rta 3 in regulating the asymmetric distribution of phosphatidylcholine across the plasma membrane and biofilm formation in Candida albicans Rta 3 in biofilm formation and phosphocholine asymmetry

Sumit, L. Panwar, D. Andes, 2017 .

Coordination of fungal biofilm development by extracellular vesicle cargo

H. Sanchez, D. Andes, M. Chevrette, 2021, Nature Communications.

Turbinmicin inhibits Candida biofilm growth by disrupting fungal vesicle-mediated trafficking.

A. Audhya, H. Sanchez, D. Andes, 2020, The Journal of clinical investigation.

Contributions of the Biofilm Matrix to Candida Pathogenesis

D. Andes, J. Nett, 2020, Journal of fungi.

Conservation and Divergence in the Candida Species Biofilm Matrix Mannan-Glucan Complex Structure, Function, and Genetic Control

W. M. Westler, A. Mitchell, P. Azadi, 2018, mBio.

Application of the systematic "DAmP" approach to create a partially defective C. albicans mutant.

A. Mitchell, D. Andes, J. Nett, 2011, Fungal genetics and biology : FG & B.

Biofilm Model albicans Candida Vivo Central Venous Catheter Development and Characterization of an In

D. Andes, J. Nett, K. Marchillo, 2004 .

The protein kinase Ire1 impacts pathogenicity of Candida albicans by regulating homeostatic adaptation to endoplasmic reticulum stress

N. Gow, D. Andes, J. Pla, 2021, Cellular microbiology.

Aspergillus Cyclooxygenase-Like Enzymes Are Associated with Prostaglandin Production and Virulence

J. Frisvad, K. Nielsen, D. Andes, 2005, Infection and Immunity.

In Vivo Pharmacodynamic Characterization of a Novel Plectasin Antibiotic, NZ2114, in a Murine Infection Model

H. Kristensen, W. Craig, D. Andes, 2009, Antimicrobial Agents and Chemotherapy.

Bacterial Infections in the Stem Cell Transplant Recipient and Hematologic Malignancy Patient.

D. Andes, E. Misch, 2019, Infectious disease clinics of North America.

Biomineral armor in leaf-cutter ants

T. Schultz, H. Bechtel, Huifang Xu, 2020, Nature Communications.

Genome Mining and Metabolomics Unveil Pseudonochelin: A Siderophore Containing 5-Aminosalicylate from a Marine-Derived Pseudonocardia sp. Bacterium.

M. K. Harper, Doug R. Braun, D. Andes, 2022, Organic letters.

Evolution of a globally unique SARS-CoV-2 Spike E484T monoclonal antibody escape mutation in a persistently infected, immunocompromised individual

D. O’Connor, Y. Kawaoka, P. Halfmann, 2022, medRxiv.

Validated Preclinical Mouse Model for Therapeutic Testing against Multidrug-Resistant Pseudomonas aeruginosa Strains

A. Stromberg, J. Gabbard, W. Severson, 2022, Microbiology spectrum.

Open access, freely available online PLoS BIOLOGY Inhibition of Mutation and Combating the Evolution of Antibiotic Resistance

Floyd E Romesberg, William A Craig, V. de Crécy-Lagard, 2022 .

Evolution of the complex transcription network controlling biofilm formation in Candida species

Kaitlin F. Mitchell, G. Butler, Eugenio Mancera, 2020, bioRxiv.

Forazoline A: marine-derived polyketide with antifungal in vivo efficacy.

Doug R. Braun, C. Myers, R. Deshpande, 2014, Angewandte Chemie.

A small molecule produced by Lactobacillus species blocks Candida albicans filamentation by inhibiting a DYRK1-family kinase

L. Cowen, P. Stogios, A. Savchenko, 2021, Nature Communications.

Managing uncertainty in antifungal dosing: antibiograms, therapeutic drug monitoring and drug-drug interactions

D. Andes, R. Lewis, 2021, Current opinion in infectious diseases.

Failure of Clindamycin To Eradicate Infection with Beta-Hemolytic Streptococci Inducibly Resistant to Clindamycin in an Animal Model and in Human Infections

W. Craig, D. Andes, J. Jorgensen, 2013, Antimicrobial Agents and Chemotherapy.

Comparative Pharmacodynamics of the New Oxazolidinone Tedizolid Phosphate and Linezolid in a Neutropenic Murine Staphylococcus aureus Pneumonia Model

W. Craig, D. Andes, K. Marchillo, 2012, Antimicrobial Agents and Chemotherapy.

Antifungal pharmacokinetics and pharmacodynamics.

D. Andes, A. Lepak, 2015, Cold Spring Harbor perspectives in medicine.

In Vivo Pharmacodynamics of Ceftobiprole against Multiple Bacterial Pathogens in Murine Thigh and Lung Infection Models

W. Craig, D. Andes, 2008, Antimicrobial Agents and Chemotherapy.

Efficacy of micafungin for the treatment of candidemia

D. Andes, N. Safdar, 2005, European Journal of Clinical Microbiology and Infectious Diseases.

Pharmacodynamics of a New Cephalosporin, PPI-0903 (TAK-599), Active against Methicillin-Resistant Staphylococcus aureus in Murine Thigh and Lung Infection Models: Identification of an In Vivo Pharmacokinetic-Pharmacodynamic Target

W. Craig, D. Andes, 2006, Antimicrobial Agents and Chemotherapy.

Reinforcement amid genetic diversity in the Candida albicans biofilm regulatory network

A. Mitchell, Gemma E. May, C. J. McManus, 2023, PLoS pathogens.

In Vivo Pharmacokinetics and Pharmacodynamics of the Lantibiotic NAI-107 in a Neutropenic Murine Thigh Infection Model

W. Craig, D. Andes, K. Marchillo, 2014, Antimicrobial Agents and Chemotherapy.

the Neutropenic Murine Thigh Infection Model 2

W. Craig, D. Andes, K. Marchillo, 2014 .

Loss of CclA, required for histone 3 lysine 4 methylation, decreases growth but increases secondary metabolite production in Aspergillus fumigatus

D. Kontoyiannis, J. Palmer, D. Andes, 2013, PeerJ.

In vivo pharmacodynamics of lefamulin, the first systemic pleuromutilin for human use, in a neutropenic murine thigh infection model

W. Craig, D. Andes, W. Wicha, 2019, The Journal of antimicrobial chemotherapy.

In Vivo Pharmacodynamic Target Assessment of Delafloxacin against Staphylococcus aureus, Streptococcus pneumoniae, and Klebsiella pneumoniae in a Murine Lung Infection Model

D. Andes, A. Lepak, 2016, Antimicrobial Agents and Chemotherapy.

Impact of Glycopeptide Resistance in Staphylococcus aureus on the Dalbavancin In Vivo Pharmacodynamic Target

D. Andes, K. Marchillo, A. Lepak, 2015, Antimicrobial Agents and Chemotherapy.

A Novel Antifungal Strategy

M. Klepser, J. Perfect, G. Parameswaran, 2010 .

Development of Modernized Acinetobacter baumannii Susceptibility Test Interpretive Criteria for Recommended Antimicrobial Agents Using Pharmacometric Approaches

D. Andes, S. Bhavnani, P. Ambrose, 2023, Antimicrobial agents and chemotherapy.

Impact of Triazole Therapeutic Drug Monitoring Availability and Timing

D. Wiebe, D. Andes, A. Lepak, 2019, Antimicrobial Agents and Chemotherapy.

Implementation of telehealth antimicrobial stewardship through partnership of an academic medical center and a community hospital.

D. Andes, W. Rose, A. Lepak, 2021, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Treatment of Community-Acquired Respiratory Tract Infections with Other Antibiotics

W. Craig, D. Andes, 2003 .

Inoculum Effects of Ceftobiprole, Daptomycin, Linezolid, and Vancomycin with Staphylococcus aureus and Streptococcus pneumoniae at Inocula of 105 and 107 CFU Injected into Opposite Thighs of Neutropenic Mice

W. Craig, D. Andes, Dong‐Gun Lee, 2013, Antimicrobial Agents and Chemotherapy.

Conserved Role for Biofilm Matrix Polysaccharides in Candida auris Drug Resistance

H. Sanchez, D. Andes, J. Nett, 2019, mSphere.

Daptomycin Dosing Based on Ideal Body Weight versus Actual Body Weight: Comparison of Clinical Outcomes

K. Buhr, J. Fish, D. Andes, 2013, Antimicrobial Agents and Chemotherapy.

In Vivo Pharmacodynamic Evaluation of Omadacycline against Staphylococcus aureus in the Neutropenic Mouse Pneumonia Model

D. Andes, K. Marchillo, A. Lepak, 2019, Antimicrobial Agents and Chemotherapy.

In Vivo Pharmacodynamics of Omadacycline against Staphylococcus aureus in the Neutropenic Murine Thigh Infection Model

D. Andes, K. Marchillo, A. Lepak, 2019, Antimicrobial Agents and Chemotherapy.

A Dual‐Responsive Antibiotic‐Loaded Nanoparticle Specifically Binds Pathogens and Overcomes Antimicrobial‐Resistant Infections

Ruosen Xie, Yuyuan Wang, S. Gong, 2021, Advanced materials.

Pharmacological Basis of CD101 Efficacy: Exposure Shape Matters

Paul G. Ambrose, D. Andes, S. Bhavnani, 2017, Antimicrobial Agents and Chemotherapy.

Regulation of Iron Transport in Streptococcus pneumoniae by RitR, an Orphan Response Regulator

J. Glasner, B. Weisblum, A. Ulijasz, 2004, Journal of bacteriology.

WCK 5222 (Cefepime-Zidebactam) Pharmacodynamic Target Analysis against Metallo-β-Lactamase-Producing Enterobacteriaceae in the Neutropenic Mouse Pneumonia Model

D. Andes, A. Lepak, Miao Zhao, 2019, Antimicrobial Agents and Chemotherapy.

Thighs of Neutropenic Mice CFU Injected into Opposite 7 and 10 5 10 Streptococcus pneumoniae at Inocula of with Staphylococcus aureus and Daptomycin, Linezolid, and Vancomycin Inoculum Effects of Ceftobiprole,

W. Craig, D. Andes, Dong‐Gun Lee, 2013 .

Preparation of Candida albicans Biofilms for Transmission Electron Microscopy.

D. Andes, H. Taff, 2013, Bio-protocol.

Identification and Characterization of Antifungal Compounds Using a Saccharomyces cerevisiae Reporter Bioassay

A. Nantel, D. Andes, J. Nett, 2012, PloS one.

Novel Keto-Alkyl-Pyridinium Antifungal Molecules Active in Models of In Vivo Candida albicans Vascular Catheter Infection and Ex Vivo Candida auris Skin Colonization

D. Krysan, D. Andes, J. Nett, 2023, Antimicrobial agents and chemotherapy.

Antifungal Efficacy of an Intravenous Formulation Containing Monomeric Amphotericin B, 5-Fluorocytosine, and Saline for Sodium Supplementation

G. Kwon, D. Andes, Jeong Yeon Kang, 2017, Pharmaceutical Research.

Pharmacodynamics of the New Des-F(6)-Quinolone Garenoxacin in a Murine Thigh Infection Model

W. Craig, D. Andes, 2003, Antimicrobial Agents and Chemotherapy.

In Vivo Pharmacodynamic Target Determination for Delafloxacin against Klebsiella pneumoniae and Pseudomonas aeruginosa in the Neutropenic Murine Pneumonia Model

D. Andes, K. Marchillo, A. Lepak, 2019, Antimicrobial Agents and Chemotherapy.

In Vivo Pharmacodynamic Target Investigation of Two Bacterial Topoisomerase Inhibitors, ACT-387042 and ACT-292706, in the Neutropenic Murine Thigh Model against Streptococcus pneumoniae and Staphylococcus aureus

D. Ritz, D. Andes, P. Seiler, 2016, Antimicrobial Agents and Chemotherapy.

Aspergillus fumigatus transcription factor ZfpA regulates hyphal development and alters susceptibility to antifungals and neutrophil killing during infection

A. Huttenlocher, D. Andes, J. Bok, 2023, PLoS pathogens.

Aspergillus fumigatus transcription factor ZfpA regulates hyphal development and alters susceptibility to antifungals and neutrophil killing during infection

A. Huttenlocher, D. Andes, J. Bok, 2023, bioRxiv.

Development of an in vitro pharmacokinetic/pharmacodynamic model in the presence of serum for studying micafungin activity against Candida albicans: a need for revision of CLSI susceptibility breakpoints.

M. Arendrup, D. Andes, J. Meletiadis, 2023, The Journal of antimicrobial chemotherapy.

Pharmacokinetic-pharmacodynamic modeling to support doripenem dose regimen optimization for critically ill patients.

D. Andes, S. Bhavnani, P. Ambrose, 2009, Diagnostic microbiology and infectious disease.

Pharmacokinetic/Pharmacodynamic Evaluation of a Novel Aminomethylcycline Antibiotic, KBP-7072, in the Neutropenic Murine Pneumonia Model against Staphylococcus aureus and Streptococcus pneumoniae

Yanli Wang, D. Andes, P. Ambrose, 2018, Antimicrobial Agents and Chemotherapy.

1248. Efficacy and Safety of Oral Ibrexafungerp in 41 Patients with Refractory Fungal Diseases, Interim Analysis of a Phase 3 Open-label Study (FURI)

G. Lyon, B. Alexander, F. Marty, 2020 .

In vivo Pharmacokinetic/Pharmacodynamic (PK/PD) Target Characterization of the Novel, Long Acting Echinocandin CD101 against C. albicans and C. glabrata in the Neutropenic Murine Disseminated Candidiasis Model

D. Andes, P. Ambrose, A. Lepak, 2017, Open Forum Infectious Diseases.

Host Contributions to Construction of Three Device-Associated Candida albicans Biofilms

J. Bernhardt, D. Mosher, D. Andes, 2015, Infection and Immunity.

Identification of triazenyl indoles as inhibitors of fungal fatty acid biosynthesis with broad-spectrum activity.

Mojca Mattiazzi Usaj, Sheena C. Li, A. Gingras, 2023, Cell chemical biology.

Editorial commentary: Antifungal therapeutic drug monitoring progress: getting it right the first time.

D. Andes, A. Lepak, 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Metabolic reprogramming during Candida albicans planktonic-biofilm transition is modulated by the ZCF15 and ZCF26 paralogs

T. Cokelaer, C. d’Enfert, Sophie Bachellier-Bassi, 2023, bioRxiv.

Outcomes by MIC Values for Patients Treated with Isavuconazole or Voriconazole for Invasive Aspergillosis in the Phase 3 SECURE and VITAL Trials

M. Ghannoum, P. Mukherjee, D. Andes, 2018, Antimicrobial Agents and Chemotherapy.

The Candida albicans reference strain SC5314 contains a rare, dominant allele of the transcription factor Rob1 that modulates biofilm formation and oral commensalism

D. Krysan, R. Bennett, M. Stamnes, 2023, bioRxiv.

Pharmacokinetics of antifungals : Implications for drug selection

D. Andes, Jean. Smith, 2006 .

Intra-Abdominal Candidiasis: The Importance of Early Source Control and Antifungal Treatment

S. Park, R. Simmons, D. Andes, 2016, PloS one.

Reply to Anaissie and Nucci and to Cisneros et al

J. Baddley, B. Kullberg, D. Andes, 2012 .

Topical delivery of ebselen encapsulated in biopolymeric nanocapsules: drug repurposing enhanced antifungal activity

D. Andes, R. Zarnowski, J. Gubernator, 2018, Nanomedicine.

Exploiting the vulnerable active site of a copper-only superoxide dismutase to disrupt fungal pathogenesis

V. Culotta, H. Sanchez, D. Andes, 2018, The Journal of Biological Chemistry.

Role of Fks1p and Matrix Glucan in Candida albicans Biofilm Resistance to an Echinocandin, Pyrimidine, and Polyene

D. Andes, J. Nett, K. Marchillo, 2010, Antimicrobial Agents and Chemotherapy.

Genetic basis of Candida biofilm resistance due to drug-sequestering matrix glucan.

H. Sanchez, D. Andes, J. Nett, 2010, The Journal of infectious diseases.

M. Pfaller, D. Andes, D. Diekema, 2010, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

In Vivo Pharmacokinetics and Pharmacodynamics of a New Triazole, Voriconazole, in a Murine Candidiasis Model

D. Andes, K. Marchillo, R. Conklin, 2003, Antimicrobial Agents and Chemotherapy.

J. Baddley, S. Lockhart, J. Ito, 2011, Journal of Clinical Microbiology.

Role of Matrix β-1,3 Glucan in Antifungal Resistance of Non-albicans Candida Biofilms

Kaitlin F. Mitchell, H. Sanchez, D. Andes, 2013, Antimicrobial Agents and Chemotherapy.

Time course global gene expression analysis of an in vivo Candida biofilm.

D. Andes, J. Nett, K. Marchillo, 2009, The Journal of infectious diseases.

Rat Indwelling Urinary Catheter Model of Candida albicans Biofilm Infection

H. Sanchez, D. Andes, J. Nett, 2014, Infection and Immunity.

Optimizing a Candida Biofilm Microtiter Plate Model for Measurement of Antifungal Susceptibility by Tetrazolium Salt Assay

D. Andes, J. Nett, Mike T. Cain, 2011, Journal of Clinical Microbiology.

Modeling of fungal biofilms using a rat central vein catheter.

D. Andes, J. Nett, K. Marchillo, 2012, Methods in molecular biology.

Association of Fluconazole Pharmacodynamics with Mortality in Patients with Candidemia

J. Baddley, D. Andes, S. Moser, 2008, Antimicrobial Agents and Chemotherapy.

Targeting Fibronectin To Disrupt In Vivo Candida albicans Biofilms

D. Mosher, D. Andes, J. Nett, 2016, Antimicrobial Agents and Chemotherapy.

Calcineurin Controls Drug Tolerance, Hyphal Growth, and Virulence in Candida dubliniensis

J. Heitman, U. Bigol, S. Filler, 2011, Eukaryotic Cell.

Novel keto-alkyl-pyridinium antifungal molecules active in models of in vivo Candida albicans vascular catheter infection and ex vivo Candida auris skin colonization

D. Krysan, D. Andes, J. Nett, 2023, bioRxiv.

Histoplasmosis complicating tumor necrosis factor-α blocker therapy: a retrospective analysis of 98 cases.

M. Money, R. Avery, D. Andes, 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

In Vivo Pharmacodynamics of Ceftobiprole against Multiple Bacterial Pathogens in Murine Thigh and Lung Infection Models

W. Craig, D. Andes, 2008, Antimicrobial Agents and Chemotherapy.

Antifungal Agents: Spectrum of Activity, Pharmacology, and Clinical Indications.

D. Andes, J. Nett, 2016, Infectious disease clinics of North America.

Clinical research in the lay press: irresponsible journalism raises a huge dose of doubt.

J. S. Daly, A. Casadevall, I. Sia, 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Phaeohyphomycosis in transplant recipients: Results from the Transplant Associated Infection Surveillance Network (TRANSNET).

G. Lyon, B. Alexander, J. Baddley, 2015, Medical mycology.

Histoplasmosis after solid organ transplant.

J. Baddley, R. Avery, D. Andes, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Drug-Drug Interaction Associated with Mold-Active Triazoles among Hospitalized Patients

D. Andes, E. Wu, C. Kelley, 2016, Antimicrobial Agents and Chemotherapy.

119. A Humanized Antibody Targeting the CotH Invasins is Protective Against Murine Mucormycosis

Yiyou Gu, A. Ibrahim, D. Andes, 2021, Open Forum Infectious Diseases.